nrxp20241031_8k.htm
false
0001719406
0001719406
2024-10-30
2024-10-30
0001719406
nrxp:CommonStockCustomMember
2024-10-30
2024-10-30
0001719406
nrxp:WarrantsToPurchaseOneShareOfCommonStockCustomMember
2024-10-30
2024-10-30
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) October 30, 2024
NRX PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
|
Delaware
|
|
001-38302
|
|
82-2844431
|
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
1201 Orange Street, Suite 600
Wilmington, Delaware 19801
(Address of principal executive offices) (Zip Code)
|
(484) 254-6134
|
|
(Registrant’s telephone number, including area code)
|
|
N/A
|
|
(Former name or former address, if changed since last report.)
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which
registered
|
|
Common Stock, par value $0.001 per share
|
|
NRXP
|
|
The Nasdaq Stock Market LLC
|
|
Warrants to purchase one share of Common Stock
|
|
NRXPW
|
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events
On October 30, 2024, NRx Pharmaceuticals, Inc., (the “Company”) issued a press release announcing the entry into a non-binding letter of intent to acquire its first Interventional Psychiatry Clinics in Florida. The non-binding letter of intent is subject to customary closing conditions, including, without limitation, the entry into definitive documentation regarding the transaction and the Company’s receipt of adequate financing.
|
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits
|
Exhibit No.
|
|
Description
|
| |
|
|
|
99.1*
|
|
|
|
104
|
|
Cover Page Interactive Data File (formatted as Inline XBRL).
|
* Furnished herewith.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
NRX PHARMACEUTICALS, INC.
|
|
|
|
|
|
|
|
Date: October 31, 2024
|
By:
|
/s/ Jonathan Javitt
|
|
|
|
Name:
|
Jonathan Javitt
|
|
|
|
Title:
|
Interim Chief Executive Officer
|
|